Non-myeloablative Conditioning Using Pentostatin, Rituximab and Denileukin Diftitox (Ontak) and Allogeneic Natural Killer Cells for Patients With Refractory Lymphoid Malignancies (MT2009-15).

Trial Profile

Non-myeloablative Conditioning Using Pentostatin, Rituximab and Denileukin Diftitox (Ontak) and Allogeneic Natural Killer Cells for Patients With Refractory Lymphoid Malignancies (MT2009-15).

Completed
Phase of Trial: Phase II

Latest Information Update: 24 May 2017

At a glance

  • Drugs Denileukin diftitox (Primary) ; Pentostatin (Primary) ; Rituximab (Primary) ; Cyclophosphamide; Fludarabine; Interleukin-2; Methylprednisolone; T cell replacement therapy
  • Indications B cell lymphoma; Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 Jan 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 20 Mar 2012 Status changed from discontinued to recruiting as reported by ClinicalTrials.gov.
    • 20 Mar 2012 Planned number of patients changed from 17 to 34 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top